Overview

Niclosamide for Mild to Moderate COVID-19

Status:
Completed
Trial end date:
2021-08-19
Target enrollment:
Participant gender:
Summary
This study will evaluate the antihelmintic drug, Niclosamide, as a potential treatment for mild to moderate coronavirus disease 2019 (COVID-19).
Phase:
Phase 2
Details
Lead Sponsor:
Tufts Medical Center
Treatments:
Niclosamide